RESULTS	Despite plasma concentrations of drug consistent with > 90 % receptor occupancy during the dosing period , the CCR3 antagonist did not significantly reduce eosinophils or eosinophil progenitor cells ( CD34 ( + ) 45 ( + ) IL-5R ( + ) ) in sputum or in blood .\